Show simple item record

AuthorAl-Shammri, Suhail
AuthorChadha, Geeti
AuthorChattopadhyay, Arpita
AuthorDoi, Suhail
Available date2023-09-13T06:04:31Z
Publication Date2023-07-03
Publication NameMedical Principles and Practice
Identifierhttp://dx.doi.org/10.1159/000530764
CitationSuhail Al-Shammri, Geeti Chadha, Arpita Chattopadhyay, Suhail Doi; The Impact of SARS-CoV-2 Infection in Unvaccinated Multiple Sclerosis Patients on Disease-Modifying Therapies. Med Princ Pract 11 July 2023; 32 (2): 143–148. https://doi.org/10.1159/000530764
ISSN10117571
URIhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85164284868&origin=inward
URIhttp://hdl.handle.net/10576/47495
AbstractObjective: Disease-modifying therapies (DMTs) in multiple sclerosis (MS) may affect the course and outcome of COVID-19, but withholding them could permit disease activity. This study aimed to understand the course of COVID-19 in unvaccinated patients with MS on disease-modifying therapies. Subjects and Methods: This descriptive study examined the course of COVID-19 among infected patients with MS followed up at a large tertiary center in Kuwait between March 1, 2020, and March 1, 2021. All subjects were outpatients at the time of data collection. Results: We studied 51 patients with MS confirmed to be infected with SARS-CoV-2 using real-time polymerase chain reaction. Of these patients, 33/51 were female, median age was 35 years (IQR 27-39 years), median Expanded Disability Status Scale score was 1.5 (IQR zero-3), and 47/51 had RRMS. B-cell-depleting agents (ocrelizumab and rituximab) were given to 19 patients, another 19 were on immune cell traffickers (fingolimod and natalizumab), and 13 were on other DMT treatments (alemtuzumab, cladribine, interferon-beta, dimethyl fumarate, and teriflunomide). 43/51 of these patients experienced mild COVID-19, not requiring hospitalization. None of the subjects experienced MS relapses during infection. Two patients on rituximab had a moderate course of the illness, which required hospitalization for oxygen support, but did not need mechanical ventilation; the rest of the subjects remained asymptomatic. Conclusions: These findings suggest that DMT may not adversely affect the course of COVID-19 in MS patients; however, patients on B-cell-depleting agents trended toward a worse outcome.
Languageen
PublisherKarger Publishers
SubjectCOVID-19 infection
Disease-modifying therapies
Multiple sclerosis
TitleThe Impact of SARS-CoV-2 Infection in Unvaccinated Multiple Sclerosis Patients on Disease-Modifying Therapies
TypeArticle
Pagination143-148
Issue Number2
Volume Number32
ESSN1423-0151
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record